 |
|
Kidney Transplantation Under FK 506
Thomas E. Starzl, MD, PhD;
John Fung, MD, PhD;
Mark Jordan, MD;
Ron Shapiro, MD;
Andreas Tzakis, MD;
Jerry McCauley, MD;
James Johnston, MD;
Yuichi Iwaki, MD;
Ashok Jain, MD;
Mario Alessiani, MD;
Satoru Todo, MD
JAMA. 1990;264(1):63-67.
Abstract
| |
The experimental immunosuppressive drug FK 506 was given to 36 renal transplant recipients, many of whom were highly sensitized. Ten were undergoing kidney retransplantation, 10 also underwent liver transplantation at an earlier time (6 patients) or concomitantly (4 patients), and 2 patients received a third organ (heart or pancreas) in addition to a liver and kidney. With follow-ups of 4 to 13 months, all but 2 of the 36 patients are alive, 29 (81%) are dialysis free, and most have good renal function. Twenty of the 29 dialysis-free patients are receiving no or low-dose (2.5 to 5.0 mg/d) prednisone therapy. Only one kidney was lost to cellular rejection. However, patients who had antidonor cytotoxic antibodies in current or historical serum samples had a high rate (3 of 9) of irreversible humoral rejection. A low incidence of posttransplant hypertension was noteworthy. Hirsutism and gingival hyperplasia were not observed. Serum cholesterol levels in patients who took FK 506 were unexpectedly low, and the effect on the level of uric acid was minimal. The side effects of FK 506 therapy include nephrotoxicity, neurotoxicity, and potential induction of a diabetic state. These are similar to the side effects of cyclosporine use, but probably less severe. The seeming safety, efficacy, and relative freedom from side effects of FK 506 encourage further trials in kidney transplantation.
(JAMA. 1990;264:63-67)
Author Affiliations
From the Departments of Surgery (Drs Starzl, Fung, Jordan, Shapiro, Tzakis, Iwaki, Jain, Alassiani, and Todo), Medicine (Drs McCauley and Johnston), and Pathology (Dr Iwaki), University Health Center of Pittsburgh, and the Veterans Administration Medical Center, University of Pittsburgh, Pa.
Footnotes
Reprint requests to Department of Surgery, 3601 Fifth Ave, Falk Clinic, Pittsburgh, PA 15213 (Dr Starzl).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Calcineurin Inhibitor Nephrotoxicity
Naesens et al.
CJASN 2009;4:481-508.
ABSTRACT
| FULL TEXT
Pathogenesis of Gout
Choi et al.
ANN INTERN MED 2005;143:499-516.
FULL TEXT
Inhibitors of Calcineurin
Holt et al.
Journal of Pharmacy Practice 2003;16:414-433.
ABSTRACT
ENCOURAGING EARLY TRANSPLANT EXPERIENCE WITH NEW IMMUNOSUPPRESSANT
JWatch General 1990;1990:2-2.
FULL TEXT
|
